News articles about Cronos Group (NASDAQ:CRON) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cronos Group earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 44.7348679426435 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Wide Variety of Cannabidiol (CBD) Based Products Creating Billion Dollar Opportunities for the Cannabis Industry (marketwatch.com)
- Edited Transcript of CRON earnings conference call or presentation 15-May-18 12:00pm GMT (finance.yahoo.com)
- Why Cronos Group Inc. Stock Jumped Again Today (fool.com)
- Cronos up 5% premarket on cannabis retail deals in Canada (seekingalpha.com)
- Cronos shares jump after reaching supply deals in Canada (proactiveinvestors.com)
Shares of CRON stock traded down $0.12 on Wednesday, hitting $8.17. 273,674 shares of the stock traded hands, compared to its average volume of 2,233,950. The company has a market capitalization of $1.16 billion and a price-to-earnings ratio of 834.00. Cronos Group has a 52 week low of $1.50 and a 52 week high of $11.90. The company has a debt-to-equity ratio of 0.02, a current ratio of 52.98 and a quick ratio of 44.71.
Several brokerages have recently weighed in on CRON. Canaccord Genuity upgraded shares of Cronos Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 15th. Beacon Securities reiterated a “buy” rating on shares of Cronos Group in a research note on Friday, May 4th.
Cronos Group Company Profile
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada.
Featured Article: How Do I Invest in Dividend Stocks
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.